MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a medical phase pharmaceutical company devoted to prolonging healthy lifespan, today revealed that the first individual has been signed up in the Company’s Phase 2 clinical test of lead prospect MYMD-1, a dental immune regulatory authority medicine, as a treatment for postponing aging and expanding healthy life expectancy.
The primary endpoint for the Phase 2 double-blind, placebo-controlled medical test is to accomplish a reduction in the distributing levels of (TNF-α), tumor necrosis variable receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the healthy proteins in the body that create inflammation as well as assist trigger the process of aging. The secondary steps of the trial will certainly be the security, tolerability, and pharmacokinetics in this populace of people.
” In a Phase 1 professional trial of MYMD-1, we demonstrated the medicine’s statistically considerable efficacy in reducing levels of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has approved TNF-α decrease as the main endpoint for our Phase 2 research, which we believe placements us well for an effective Phase 2 outcome,” said Chris Chapman, M.D., President, Director and also Principal Medical Officer of MyMD. “The initiation of client registration in this study developments our goal to slow down the aging procedure, protect against loss of muscle cells in aging, limit frailty, and expand healthy life expectancy.”
MyMD has actually specified that there are no FDA-approved medications for treating aging disorders and also extending healthy and balanced life expectancy human beings, a market expected to be a minimum of $600 billion by 20251 according to a significant investment bank. TNF-α blockers are the most recommended medicines by earnings, a global market of about $40 billion per year,2 as well as, according to Nature Aging journal,3 a slowdown in maturing that would certainly raise life expectancy by one year is worth $38 trillion and also by one decade deserves $367 trillion.
Along with aging, MYMD-1’s distinct action in controling the body immune system as well as treating chronic swelling is being established for the treatment of autoimmune illness, including rheumatoid arthritis (RA), several sclerosis (MS), diabetes mellitus, as well as inflammatory digestive tract disease.
” We intend to start writing protocols for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The increasing occurrence of rheumatoid joint inflammation and various other autoimmune and also inflammatory conditions are driving demand for TNF preventions like MYMD-1, and our company believe our orally carried out medicine with really low toxicity would certainly be disruptive to the $60 billion market for RA if authorized by the FDA for this indicator.”
Rheumatoid arthritis impacts approximately 40 million people globally.4.
Concerning MYMD-1.
Initially developed for autoimmune diseases, MYMD-1’s primary function is to reduce the aging process, protect against sarcopenia and also frailty, as well as extend healthy life expectancy. Since it can cross the blood-brain barrier and also gain access to the main nerves (CNS), MYMD-1 is likewise placed to be a feasible treatment for brain-related conditions. Its system of activity and also efficiency in illness including multiple sclerosis (MS) as well as thyroiditis have been researched through collaborations with numerous scholastic establishments. MYMD-1 is likewise revealing pledge in pre-clinical research studies as a potential therapy for message- COVID-19 problems and as an anti-fibrotic as well as anti-proliferation therapeutic.
MYMD-1 has actually revealed efficiency in pre-clinical researches in controling the immune system by performing as a selective prevention of growth necrosis factor-alpha (TNF-α), a motorist of chronic swelling. Unlike various other treatments, MYMD-1 has actually been displayed in these pre-clinical researches to selectively block TNF-α when it ends up being overactivated in autoimmune diseases as well as cytokine storms, however not obstruct it from doing its regular work of being a very first -responder to any kind of regular sort of modest infection. MYMD-1’s convenience of dental dosing is an additional differentiator compared to currently available TNF-α blockers, every one of which call for shipment by shot or infusion. No accepted TNF inhibitor has actually ever been dosed by mouth. Furthermore, the medication is not immunosuppressive and has actually not been shown to cause the serious adverse effects common with conventional treatments that deal with swelling.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical firm committed to expanding healthy and balanced lifespan, is focused on establishing two novel restorative systems that treat the root causes of illness rather than just dealing with the signs. MYMD-1 is a medicine platform based on a medical phase small particle that regulates the immune system to manage TNF-α, which drives persistent swelling, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, boost durability, and treat autoimmune diseases as well as COVID-19- associated depression. The Business’s 2nd medication platform, Supera-CBD, is being developed to treat chronic discomfort, dependency and also epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and is being developed to attend to and improve upon the rapidly growing CBD market, which includes both FDA authorized drugs and also CBD products not currently regulated as drugs. To find out more, go to www.mymd.com.
